A Node in a Global Network
Our ADRC is a highly active node in research on AD and related disorders, on a national and international level. Our highly networked position relates in part to the center’s 24-year history as one of the longest-established ADRCs, with extensive clinical and basic research on Alzheimer’s Disease and other neurodegenerative disorders. But it also relates to special ADRC resources including
- an unusually ethnically diverse population with high proportions of Hispanics and African-Americans;
- the exceptionally large and accessible neuropathological brain bank; and
- the extensive genetic efforts at Columbia, which has been the original “home” of the NIA-LOAD study.
The ADRC is a collaborating or contributing member to a large complex of consortia, funded by NIH, the Alzheimer’s Association, or international bodies. These include inter-center repositories of clinical information such as NACC (National Alzheimer’s Coordinating Center) and of DNA samples such as NCRAD (National Cell Repository for Alzheimer’s Disease). And these also include a large number of genetics collaborative efforts in which Columbia is a strong member. Columbia ADRC investigators are the principals, for NIA-LOAD (the National Institute on Aging, Late Onset Alzheimer’s Disease), and on the steering committees or strongly contributing to other consortia, including ADGC (Alzheimer’s Disease Genetics Consortium), IGAP (International Genetics of Alzheimer’s Disease Project), and DIAN (Dominantly Inherited Alzheimer’s Network). The ADRC actively collaborates in a variety of other non-Alzheimer’s disease networks and projects involving genetics or tissue sharing including the National Prion Disease Surveillance Center. Dr. Mayeux is also one of the lead investigators of the Alzheimer’s Disease Sequencing Project currently underway.
The ADRC collaborates in educating families and providing subjects for a wide variety of clinical trials including NIA-and NINDS-sponsored efforts including the Alzheimer’s Disease Neuroimaging Initiative studies ADNI, and DOD-ADNI, the Alzheimer’s Disease Cooperative Study and the Alzheimer's TherapeuticResearch Institute (ATRI). We also participate in a wide range of national and international, pharmaceutical industry-sponsored studies including studies of crenezumal, solanezumab, MU-8931, AZO-3293, idalopirdine and azeliragon. For a number of these, Columbia investigators have been members of or chairs of the steering committee.